Main Achievements |
[1] Bi X, Li F, Liu S, Jin Y, Zhang X, Yang T, Dai Y, Li X,Zhao AZ*. (2017) ω-3 polyunsaturated fatty acids ameliorate type 1 diabetes and autoimmunity. J Clin Invest. 2017 May 1;127(5):1757-1771. [2] Cheng, Lixian，Shi, Hui，Jin, Yan，Li, Xiaoxi，Pan, Jinshun，Lai, Yimei，Lin, Yan，Jin, Ya，Roy, Gaurab，Zhao, Allan*，Li, Fanghong*. (2016) Adiponect in Deficiency Leads to Female Subfertility and Ovarian Dysfunctions in Mice.，Endocrinology，157(12)：4875~4887. [3] Li, Jie，Wei, Dong，McCrory, Mark A，Szalai, Alexander J，Yang, Gangyi，Li, Ling，Li, Fanghong(*)，Zhao, Allan Z *. (2016) Human C-reactive protein impedes entry of leptin into the CNS and attenuates its physiological actions in the CNS.，Biochem J，473(9): 1215~1224. [4] Zhou S, Zhao Z, Lin Y, Gong S, Li F, Pan J, Li X, Gao Z,Zhao AZ*. (2016) Suppression of pancreatic ductal adenocarcinoma growth by intratumoral delivery of attenuated Salmonella typhimurium using a dual fluorescent live tracking system. Cancer Biol Ther, 17(7):732-40. [5] Pan J, Cheng L, Bi X, Zhang X, Liu S, Bai X, Li F,Zhao AZ*. (2015) Elevation of ω-3 Polyunsaturated Fatty Acids Attenuates PTEN-deficiency Induced Endometrial Cancer Development through Regulation of COX-2 and PGE2 Production. Sci Rep. 5:14958. [6] Wei, D., Li, J., Shen, MD, Jia,W, Tian,H., Dai,Y., andZhao, AZ *. (2010) Cellular Production of n-3 PUFAs and Reduciton of n-6/n-3 ratios in the Pancreatic b-cells and Islets Enhance Insulin Secretion and Confer Protection against Cytokine-induced Cell Death. Diabetes. 59: 471-478. [7] Cong L, Gasser J, Zhao J, Yang B, Li F,Zhao AZ *.(2007) Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL95- Endocr Relat Cancer. 14(3): 713-20. [8] Cong L, Chen K, Li J, Gao P, Li Q, Mi S, Wu X,Zhao AZ *. (2007) Regulation of adiponectin and leptin secretion and expression by insulin through a PI3K-PDE3B dependent mechanism in rat primary adipocytes. Biochem J. 403(3): 519-25. [9] Chen, K., Li, FH, Li, J., Cai, H., Strom, S., Bisello, A., Friedman-Einat, M., Kelley, DE, McCroy, M., Szalai, A.,Zhao, AZ *. (2006) Induction of Leptin Resistance through Direct Interaction ofC-Reactive Protein with Leptin. Nature Medicine 12: 425-432. [10] Li, J, Li, F, andZhao, AZ *. (2006) Inflammation and Leptin，Drug Discovery Today: Disease Mechanisms 3 (3): 387-393. [11] Huan, J.N., Li, J., Han, Y.P., Chen, K., Wu, N., andZhao, A.Z*. (2003) Adipocyte-Selective Reduction of the Leptin Receptors Induced by Antisense-RNA Leads to Increased Adiposity, Dyslipidemia and Insulin Resistance. J. Biol. Chem. 278: 45638-45650. [12]Zhao, A.Z., Huan, J.N. and Sahu, A. (2002) Requirement of a PI3K-PDE3B-cAMP Pathway for the Satiety Function of Leptin in the Hypothalamus. Nature Neuroscience 5:727-728. [13]Zhao, A.Z., Shinohara, M., Huang, D., Eldar-Finkelman, H., Krebs, E.G., Beavo, J.A. and Bornfeldt, K.E. (2000) Leptin Antagonizes the Action of Glucagon by Activating Phosphodiesterase 3B in Primary Hepatocytes. J. Biol. Chem. 275:11348-11354. [14]Zhao, A.Z., Bornfeldt, K.E., and Beavo, JA. (1998) Leptin Inhibition of Insulin Secretion through Activation of Phosphodiesterase 3B.J. Clinc. Inves. 102: 869-873. [15]Zhao, A.Z., Zhao, H., Teague, J., Fujimoto, W., and Beavo, J.A. (1997) Attenuation of Insulin Secretion by Insulin-like Growth Factor 1 Is Mediated through Activation of Phosphodiesterase 3B. Proc. Natl. Acad. U.S.A. 94: 3223-3228. Patents authorized in recent years: 1 genetically engineered battery for treatment of break cage, method for constructing the battery, and applications threeo, invention patent, U.S.A., patent No. 14766558, date of announcement 2017-09-13 2 Application of an attenuated Salmonella typorium invention patent, USA, patent No. 9439934, date of authorization announcement: August 24, 2016 3 genetically engineered bacterium for treatment of break cage, patent for invention, Australia, patent No.: 2014223112, date of announcement: February 3, 2017 4 Application of attenuated Salmonella typhimurium and its genetically engineered bacteria in the preparation of drugs for the treatment of pancreatic cancer, invention patent, China, patent No.: zl201310688936.3, date of authorization announcement: February 24, 2016 5. A genetically engineered bacterium for the treatment of breast cancer and its construction method and application, invention patent, China, patent No.: zl201310062253.7, authorized announcement date: December 31, 2014 6 Application of attenuated Salmonella typhimurium and its genetically engineered bacteria in the preparation of prostate cancer drugs, patent for invention, China, patent No.: zl201410183149.8, date of authorization announcement: August 8, 2018 7 compositions for blocking the innovation effect of invention patent, U.S.A., patent No. 7629315, announcement date of authorization: December 8, 2009 Patent pending: 1. Application of genetically engineered bacteria vnp2009-m in the preparation of lung cancer prevention and treatment drugs, invention patent, Hong Kong, China, patent application No. 18100076.7, application date: January 3, 2018, preliminary examination stage 2. Application of genetically engineered bacteria vnp2009-m in the preparation of drugs for the treatment of malignant sarcoma, invention patent, Hong Kong, China, patent application No. 18101397.7, application date: January 29, 2018, preliminary examination stage 3. Application of genetically engineered bacteria vnp2009-m in the preparation of drugs for prevention and treatment of cancer metastasis, invention patent, China, patent application No. 2016100812709 application date: February 5, 2016, substantive examination stage |
